CN108261505B - Medicine for treating hypertension and cerebral infarction and preparation method thereof - Google Patents
Medicine for treating hypertension and cerebral infarction and preparation method thereof Download PDFInfo
- Publication number
- CN108261505B CN108261505B CN201711056389.1A CN201711056389A CN108261505B CN 108261505 B CN108261505 B CN 108261505B CN 201711056389 A CN201711056389 A CN 201711056389A CN 108261505 B CN108261505 B CN 108261505B
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- root
- cerebral infarction
- treating hypertension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/237—Notopterygium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/424—Gynostemma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a preparation method of a medicine for treating hypertension and cerebral infarction, which is an oral liquid prepared from the following raw materials in parts by weight according to a conventional preparation method: 15-50 parts of astragalus membranaceus, 10-40 parts of salvia miltiorrhiza, 10-30 parts of hawthorn, 8-32 parts of gynostemma pentaphylla, 2-30 parts of medicinal cyathula root, 2-30 parts of caulis spatholobi, 2-20 parts of notopterygium root, 1-15 parts of frankincense, 1-15 parts of myrrh, 2-25 parts of peach kernel, 2-25 parts of safflower, 2-25 parts of cassia twig, 2-25 parts of ramulus mori, 2-25 parts of red paeony root, 2-18 parts of ligusticum wallichii, 2-18 parts of angelica sinensis, 2-20 parts of earthworm, 2-30 parts of gastrodia elata, 5-35 parts of uncaria, 4-30 parts of selfheal, 2-18 parts of leech, 2-30 parts of herba siegesbeckiae, 2-30 parts of eucommia ulmoides and 2-25. The results of clinical observation and verification of hundreds of cases show that the total effective rate of the medicine for treating hypertension and cerebral infarction is 97.5 percent, the cure rate is high, the treatment period is short, and the medicine has no toxic or side effect on human bodies and is easy to popularize and use.
Description
Technical Field
The invention belongs to the field of traditional Chinese medicine compositions, and particularly relates to a preparation method of a medicine for treating hypertension and cerebral infarction.
Background
Hypertension and cerebral infarction are common diseases of human bodies, and the pathogenic reasons under the traditional Chinese medicine theory are as follows: qi is the commander of blood, blood is the mother of qi, and the above diseases are caused by the deficiency of vital qi, qi deficiency and blood stagnation after human stroke, and the deficiency of vital qi and blood can not move, so that the stagnation of veins and vessels can cause the loss of nourishment of muscles and tendons, blood stagnation and slow and smooth, blood supply of the brain is insufficient, blood stasis can be formed for a long time, the blood pressure is raised, and infarction and thrombus are generated, so that hemiplegia, facial distortion and other clinical manifestations can be seen.
The traditional Chinese medicine considers that the occurrence and development processes of any disease are all the results of the excess and decline of yin and yang of the organism and the dysfunction of viscera and meridians due to pathogenic factors acting on the human body; the basic principle of traditional Chinese medicine for preventing and treating diseases is as follows: eliminating pathogenic factors, strengthening body resistance, consolidating constitution, coordinating viscera and meridians, and correcting preponderance and decline of yin and yang to restore normal state of yin-yang.
The western medicine considers that hypertension and cerebral infarction are symptoms of organ ischemic necrosis, are mostly caused by people over 50-60 years old, have high mortality rate, often have atherosclerosis and hypertension, have prodromal symptoms before onset of disease, and are clinically manifested by symptoms of facial distortion, hemiplegia, watery mouth, eating food, lifting chopsticks, headache, dizziness, transient numbness of limbs and the like, the onset of disease is generally slow, patients mostly develop diseases in silence and sleep, and the symptoms of most patients reach the peak through a few hours or even 1-3 days.
At present, the common western medicines for clinically treating hypertension comprise antihypertensive capsules, sanjingshila tablets, birthday dates, antihypertensive No. 0 and the like, and the traditional Chinese medicines comprise eucommia bark antihypertensive tablets, bezoar antihypertensive tablets and the like, and the traditional Chinese medicines and the western medicines have long administration time for treating hypertension, and once the medicines are stopped, the blood pressure rises and rebounds again; the western medicines for treating cerebral infarction comprise betahistine hydrochloride oral liquid, brain protein hydrolysate tablets, aspirin enteric-coated tablets and the like, the taking time is as long as 3-5 years, the treatment period is long, the cost is high, the cure rate is low, the side effect is generated when the western medicines are taken for a long time, the liver and kidney functions are damaged, the traditional Chinese medicines for treating cerebral infarction comprise ginkgo leaves, salvia miltiorrhiza tablets, naoxintong, Xuesaitong and the like, the product stability is poor, and the effect is slow.
Disclosure of Invention
Aiming at the problems and defects in the prior art, the invention provides a medicine for treating hypertension and cerebral infarction, which has the advantages of short treatment period, low cost, high cure rate and no toxic or side effect on human bodies.
The technical scheme for solving the technical problems is as follows: a medicine for treating hypertension and cerebral infarction is prepared from the following raw materials (by weight portion) through conventional process.
15-50 parts of astragalus membranaceus, 10-40 parts of salvia miltiorrhiza, 10-30 parts of hawthorn, 8-32 parts of gynostemma pentaphylla, 2-30 parts of medicinal cyathula root, 2-30 parts of caulis spatholobi, 2-20 parts of notopterygium root, 1-15 parts of frankincense, 1-15 parts of myrrh, 2-25 parts of peach kernel, 2-25 parts of safflower, 2-25 parts of cassia twig, 2-25 parts of ramulus mori, 2-25 parts of red paeony root, 2-18 parts of ligusticum wallichii, 2-18 parts of angelica sinensis, 2-20 parts of earthworm, 2-30 parts of gastrodia elata, 5-35 parts of uncaria, 4-30 parts of selfheal, 2-18 parts of leech, 2-30 parts of herba siegesbeckiae, 2-30 parts of eucommia ulmoides and 2-25.
The medicine of the invention is prepared from the following raw materials in parts by weight:
25-40 parts of astragalus membranaceus, 15-35 parts of salvia miltiorrhiza, 12-25 parts of hawthorn, 16-22 parts of gynostemma pentaphylla, 8-22 parts of medicinal cyathula root, 8-22 parts of caulis spatholobi, 8-15 parts of notopterygium root, 4-11 parts of frankincense, 4-11 parts of myrrh, 6-18 parts of peach kernel, 6-18 parts of safflower, 6-18 parts of cassia twig, 6-18 parts of ramulus mori, 6-18 parts of red peony root, 5-12 parts of ligusticum wallichii, 5-12 parts of angelica sinensis, 8-15 parts of earthworm, 8-22 parts of gastrodia elata, 10-25 parts of uncaria, 10-22 parts of selfheal, 5-12 parts of leech, 8-22 parts of herba siegesbeckiae, 8-22 parts of eucommia ulmoides and 6-18 parts.
The optimal weight portion ratio of the raw materials for preparing the medicine of the invention is as follows:
35 parts of astragalus membranaceus, 25 parts of salvia miltiorrhiza, 20 parts of hawthorn, 18 parts of gynostemma pentaphylla, 10 parts of medicinal cyathula root, 10 parts of caulis spatholobi, 9 parts of notopterygium root, 5 parts of frankincense, 5 parts of myrrh, 8 parts of peach kernel, 8 parts of safflower, 8 parts of cassia twig, 8 parts of ramulus mori, 8 parts of red paeony root, 6 parts of ligusticum wallichii, 6 parts of angelica sinensis, 9 parts of earthworm, 10 parts of rhizoma gastrodiae, 15 parts of uncaria, 12 parts of selfheal, 6 parts of leech, 10 parts of herba siegesbeckiae, 10 parts of eucommia ulmoides and.
The medicine can be prepared into any type of medicine suitable for clinical use according to the conventional preparation process, such as pills, tablets, capsules, powder, oral liquid and the like.
The preferred medicine dosage form of the medicine is oral liquid, and the preparation method comprises the following steps:
the seven doses of the raw materials are taken according to the weight portion proportion of claim 3, the raw materials are filled into a medicine bag and sealed, 5000-6000 ml of water is added for soaking for 1 hour, then the soaked water and the medicine bag are filled into an automatic medicine decocting machine, decoction is carried out for forty-five minutes by slow and strong fire, dregs are removed after decoction liquid is taken out, the medicine liquid is bagged by a machine, each bag is 200ml, and the medicine liquid is placed in a refrigerator for cold storage for standby.
The effects of the traditional Chinese medicines in the formula, the compatibility of the medicines in the formula and monarch, minister, assistant and guide are explained in detail as follows:
the deficiency of both qi and blood is the root cause of the disease, and the medicine of the invention takes qi deficiency as the basis, blood deficiency as the standard, qi tonifying as the main part and blood circulation promoting, blood stasis removing and collateral dredging as the auxiliary part. The astragalus is added in the formula of the medicine for treating hypertension and cerebral infarction, so that the medicine is a monarch drug, can tonify primordial qi, is meant for sufficient qi, can promote blood circulation when qi is strong, and can remove blood stasis and remove collaterals when blood circulation is promoted.
The leech breaks blood and unblocks collaterals, removes stasis and eliminates mass, and the earthworm drug is added to promote blood circulation and remove stasis, so that the leech can play the efficacies of dredging the channels and collaterals of the whole body, calming wind and relieving pain and reducing blood pressure, and is a ministerial drug.
Chinese angelica has the functions of enriching and nourishing blood; the rhizoma ligustici wallichii is used for activating blood and promoting qi circulation, dispelling wind and relieving pain, and is used together with the angelica to have the effects of benefiting qi and nourishing blood of the astragalus; the large dose of the salvia miltiorrhiza bunge has the effects of promoting blood circulation, removing blood stasis, expanding blood vessels, improving microcirculation, reducing blood pressure, reducing blood viscosity, and breaking blood stasis and supplementing new blood; peach kernel has the actions of breaking blood and removing stasis, moistening dryness; safflower promotes blood circulation to remove meridian obstruction, removes blood stasis to relieve pain, and promotes blood circulation; the red paeony root has the functions of clearing heat and cooling blood, promoting blood circulation, removing blood stasis and relieving pain, and improving blood circulation, and can enhance the effects of promoting blood circulation, removing blood stasis, clearing and activating the channels and collaterals and reduce serum cholesterol by jointly using; olibanum and Myrrha can be used for promoting blood circulation, relieving pain, activating qi-flowing, and can be used together with caulis Spatholobi for relaxing muscles and tendons, activating collaterals, replenishing blood, promoting blood circulation, and relieving various symptoms; the selfheal dissipating stagnation and relieving swelling, purging liver fire and reducing blood pressure; ramulus Uncariae cum uncis has effects of suppressing hyperactive liver, calming endogenous wind, relieving pain, and lowering blood pressure; the gastrodia elata can calm wind and relieve pain, calm liver yang, dispel wind and dredge collaterals, and reduce blood pressure, and can calm liver yang, calm wind and relieve pain, reduce blood pressure, and activate blood first when used together, and can self-extinguish when used for treating wind; eucommia bark has the effects of tonifying liver and kidney, strengthening muscles and bones and reducing blood pressure; herba Taxilli has effects of dispelling pathogenic wind and removing dampness, invigorating kidney, strengthening tendons, and lowering blood pressure; the herba siegesbeckiae has the effects of dredging channels and collaterals, benefiting joints, dispelling wind-damp, and lowering blood pressure, and can enhance the synergistic effects of nourishing liver and kidney, dredging channels and collaterals, benefiting joints and lowering blood pressure when used together; the hawthorn fruit has the effects of promoting the circulation of qi, dissipating blood stasis, promoting digestion and reducing blood fat, and is used together with the gynostemma pentaphylla to tonify qi, strengthen the spleen and strengthen the effects of activating blood and reducing blood fat.
Radix cyathulae not only can promote blood circulation and remove meridian obstruction, but also can be used for guiding the medicine to flow down to the focus; the cassia twig and the mulberry twig are good at expelling wind-damp and dredging the channels and collaterals, and can circulate blood at the tail ends of the limbs; notopterygium root, rhizoma Notopterygii, as guiding drugs, ascends to the focus of the head, and is used as "guiding drugs".
In order to verify the treatment effect of the liquid medicine preparation on hypertension and cerebral infarction, the applicant entrusts the liquid medicine preparation to the clinic observation test of 200 patients with hypertension and cerebral infarction by the department of traditional Chinese medicine outpatient service of the first hospital in Yulin city, Shanxi province, and the test result shows that 120 patients with hypertension and cerebral infarction are treated by the oral liquid medicine preparation of the invention, the cure rate is 60%, the effective rate is 20 patients, the effective rate is 27.5%, the ineffective rate is 2.5%, and the total effective rate is 97.5%.
Detailed Description
The present invention will be described in further detail with reference to examples, but the present invention is not limited to these examples. The raw materials for the test included: radix astragali, radix Salviae Miltiorrhizae, fructus crataegi, herba Gynostemmatis, radix Cyathulae, caulis Spatholobi, rhizoma Et radix Notopterygii, Olibanum, Myrrha, semen Persicae, flos Carthami, ramulus Cinnamomi, ramulus Mori, radix Paeoniae Rubra, rhizoma Chuanxiong, radix Angelicae sinensis, Pheretima, rhizoma Gastrodiae, ramulus Uncariae cum uncis, Spica Prunellae, Hirudo, herba Siegesbeckiae, cortex Eucommiae, and herba Taxilli.
Test example 1 toxicity test
The astragalus, the salvia miltiorrhiza, the hawthorn, the gynostemma pentaphylla, the medicinal cyathula root, the suberect spatholobus stem, the notopterygium root, the frankincense, the myrrh, the peach kernel, the safflower, the cassia twig, the ramulus mori, the red paeony root, the szechuan lovage rhizome, the Chinese angelica, the earthworm, the tall gastrodia tuber, the uncaria, the selfheal, the leech, the siegesbeckia herb, the eucommia bark and the parasitic loranthus are all traditional Chinese medicinal materials which are used conventionally, and the traditional Chinese medicines are prepared into.
Acute toxicity test: an acute toxicity test is carried out by using 80 NIH mice, SPF (specific pathogen free) level, half male and female and 16-22 g of body weight. Mice are randomly divided into two groups of administration groups and control groups, each group comprises 40 mice, the mice are fasted for 12 hours before the experiment, the medicine is decocted into liquid to make the concentration of the crude drug be 4.0 g/mL, the intragastric administration mode is adopted, the intragastric volume is 4.5mL/kg, the control group is administered with normal saline, the administration is carried out for 2 times a day, the administration interval time is 6 hours, the mice are continuously observed for 14 days after the administration, and the toxic reaction and the death number of the mice are recorded. The test result shows that compared with the control group, the mice of the administration group have no obvious abnormality, and the whole body condition, diet, drinking water and weight growth of the mice are normal after the test is continuously observed for 14 days. Mice in a sacrifice administration group are selected, and important organs such as heart, liver, spleen, lung, stomach and thymus of the mice are examined under a microscope, and no obvious abnormality is found. Therefore, the external medicine has low acute toxicity and safe clinical medication.
Long-term toxicity test: SD rats with body weight of 200g +/-10 g and male and female halves are used. The medicine is decocted into liquid for testing, three dosage groups of high dosage, medium dosage and low dosage are prepared, the dosage is respectively 20 times, 10 times and 5 times of the clinical dosage of an adult, the stomach irrigation administration mode is adopted, the medicine is continuously administered for 20 weeks, and after the medicine is stopped for 4 weeks, the test result shows that: the medicament has no obvious influence on indexes such as hair, behaviors, excrement and urine, body weight, visceral weight, hemogram, liver and kidney functions, blood sugar, blood fat and the like of a rat, and the visual observation of the visceral organs shows no obvious abnormality and histological examination results show that each visceral organ of the rat has no obvious change after the medicament is stopped for 4 weeks after 20 weeks. The external medicine has low toxicity after long-term administration to rats, has no obvious abnormal reaction after stopping administration, and is safe to apply.
Test example 2 clinical test
The formula of the invention with the best weight proportion is as follows: the oral liquid is prepared from 35 parts of astragalus membranaceus, 25 parts of salvia miltiorrhiza, 20 parts of hawthorn, 18 parts of gynostemma pentaphylla, 10 parts of medicinal cyathula root, 10 parts of caulis spatholobi, 9 parts of notopterygium root, 5 parts of frankincense, 5 parts of myrrh, 8 parts of peach kernel, 8 parts of safflower, 8 parts of cassia twig, 8 parts of mulberry twig, 8 parts of red peony root, 6 parts of ligusticum wallichii, 6 parts of angelica sinensis, 9 parts of earthworm, 10 parts of gastrodia elata, 15 parts of uncaria, 12 parts of selfheal, 6 parts of leech, 10 parts of herba siegesbeckiae, 10 parts of eucommia ulmoides and 8 parts of loranthus parasiticus, and is used for clinically observing and treating patients with hypertension and cerebral infarction at age of 41-76 years.
The taking method comprises the following steps: the liquid preparation is orally taken 3 times a day, a fixed 200ml medicine bag is heated and orally taken half an hour after each meal, one month is a treatment course, and the total treatment course is 1 to 6. In the clinical test process, the patient should strictly follow the taking matters, in addition, the patient should not take other medicines for treating the disease, the work and rest rule should be kept, the diet is light, the mood is smooth, after taking 1-6 treatment courses, and after 3 months, the patient is revisited every 2 months and the test result is recorded.
Example 1
A preparation method of a medicine for treating hypertension and cerebral infarction comprises the following steps:
the seven doses of the raw materials are taken according to the weight part ratio of claim 3, the raw materials are filled into a medicine bag and sealed, 5000-6000 ml of water is added for soaking for 1 hour, then the soaked water and the medicine bag are filled into an automatic medicine decocting machine, the medicine bag is bagged by the machine after being decocted for forty-five minutes by slow and strong fire, each bag is 200ml, and the medicine bag is placed in a refrigerator for cold storage and standby.
Example 2
A medicine for treating hypertension and cerebral infarction is prepared from the following raw materials in parts by weight:
15 parts of astragalus membranaceus, 10 parts of salvia miltiorrhiza, 10 parts of hawthorn, 8 parts of gynostemma pentaphylla, 2 parts of medicinal cyathula root, 2 parts of caulis spatholobi, 2 parts of notopterygium root, 1 part of frankincense, 1 part of myrrh, 2 parts of peach kernel, 2 parts of safflower, 2 parts of cassia twig, 2 parts of ramulus mori, 2 parts of red paeony root, 2 parts of ligusticum wallichii, 2 parts of angelica sinensis, 2 parts of earthworm, 2 parts of rhizoma gastrodiae, 5 parts of uncaria, 4 parts of selfheal, 2 parts of leech, 2 parts of herba siegesbeckiae, 2 parts of eucommia ulmoides and.
Example 3
A medicine for treating hypertension and cerebral infarction is prepared from the following raw materials in parts by weight:
25 parts of astragalus membranaceus, 15 parts of salvia miltiorrhiza, 12 parts of hawthorn, 16 parts of gynostemma pentaphylla, 8 parts of medicinal cyathula root, 8 parts of caulis spatholobi, 8 parts of notopterygium root, 4 parts of frankincense, 4 parts of myrrh, 6 parts of peach kernel, 6 parts of safflower, 6 parts of cassia twig, 6 parts of ramulus mori, 6 parts of red paeony root, 5 parts of ligusticum wallichii, 5 parts of angelica sinensis, 8 parts of earthworm, 8 parts of rhizoma gastrodiae, 10 parts of uncaria, 10 parts of selfheal, 5 parts of leech, 8 parts of herba siegesbeckiae, 8 parts of eucommia ulmoides and.
Example 4
A medicine for treating hypertension and cerebral infarction is prepared from the following raw materials in parts by weight:
40 parts of astragalus membranaceus, 35 parts of salvia miltiorrhiza, 25 parts of hawthorn, 22 parts of gynostemma pentaphylla, 22 parts of medicinal cyathula root, 22 parts of caulis spatholobi, 15 parts of notopterygium root, 11 parts of frankincense, 11 parts of myrrh, 18 parts of peach kernel, 18 parts of safflower, 18 parts of cassia twig, 18 parts of ramulus mori, 18 parts of red paeony root, 12 parts of ligusticum wallichii, 12 parts of angelica sinensis, 15 parts of earthworm, 22 parts of rhizoma gastrodiae, 25 parts of uncaria, 22 parts of selfheal, 12 parts of leech, 22 parts of herba siegesbeckiae, 22 parts of eucommia ulmoides and.
Example 5
A medicine for treating hypertension and cerebral infarction is prepared from the following raw materials in parts by weight:
35 parts of astragalus membranaceus, 25 parts of salvia miltiorrhiza, 20 parts of hawthorn, 18 parts of gynostemma pentaphylla, 10 parts of medicinal cyathula root, 10 parts of caulis spatholobi, 9 parts of notopterygium root, 5 parts of frankincense, 5 parts of myrrh, 8 parts of peach kernel, 8 parts of safflower, 8 parts of cassia twig, 8 parts of ramulus mori, 8 parts of red paeony root, 6 parts of ligusticum wallichii, 6 parts of angelica sinensis, 9 parts of earthworm, 10 parts of rhizoma gastrodiae, 15 parts of uncaria, 12 parts of selfheal, 6 parts of leech, 10 parts of herba siegesbeckiae, 10 parts of eucommia ulmoides and.
Example 6
A medicine for treating hypertension and cerebral infarction is prepared from the following raw materials in parts by weight:
50 parts of astragalus membranaceus, 40 parts of salvia miltiorrhiza, 30 parts of hawthorn, 32 parts of gynostemma pentaphylla, 30 parts of medicinal cyathula root, 30 parts of caulis spatholobi, 20 parts of notopterygium root, 15 parts of frankincense, 15 parts of myrrh, 25 parts of peach kernel, 25 parts of safflower, 25 parts of cassia twig, 25 parts of ramulus mori, 25 parts of red paeony root, 18 parts of ligusticum wallichii, 18 parts of angelica sinensis, 20 parts of earthworm, 30 parts of rhizoma gastrodiae, 35 parts of uncaria, 30 parts of selfheal, 18 parts of leech, 30 parts of herba siegesbeckiae, 30 parts of eucommia ulmoides and 25.
In order to verify the treatment effect of the liquid pharmaceutical preparation of the invention on hypertension and cerebral infarction, the applicant entrusts the clinic observation test to 200 patients with hypertension and cerebral infarction by using the liquid pharmaceutical preparation of the invention to the department of outpatient service of traditional Chinese medicine of the first hospital in elming city in Shanxi, the test conditions are as follows:
1. clinical data
The total 200 cases of hypertension and cerebral infarction diseases are selected from outpatients, wherein the ages of the 200 cases are the minimum age of 41 years and the maximum age of 76 years, the ages of 41-55 are 25 cases, the ages of 55-65 are 135 cases and the ages of 65-76 are 40 cases, and the disease course is shortest 1 month and longest 6 months.
2. Diagnostic criteria
The nuclear magnetic resonance vibration examination result shows cerebral infarction, clinical manifestations of facial distortion, hemiplegia, sialorrhea, limb numbness, aphasia, headache, dizziness, blood pressure 140/100 mmHg-220/130 mmHg, and high blood fat.
3. Standard of therapeutic effect
The nuclear magnetic resonance vibration supply examination is not abnormal, all clinical manifestation symptoms are normal, the blood pressure and the blood fat are normal, and the disease is not relapsed after being maintained for more than 2-3 years.
4. Method of treatment
The liquid preparation is orally taken 3 times a day, a fixed 200ml medicine bag is heated and orally taken half an hour after each meal, and seven doses are taken in seven days.
5. Standard of therapeutic effect
And (3) healing: the blood pressure and the blood fat are normal, the headache and the dizziness disappear, the limbs move freely, and the language expression is smooth; the effect is shown: the clinical symptoms and physical signs are obviously improved; the method has the following advantages: those with improved clinical symptoms and signs; and (4) invalidation: the clinical symptoms and signs are not improved.
6. Therapeutic results
Among 200 patients with hypertension and cerebral infarction, 120 patients are cured to 60 percent, 20 patients are remarkably effective to 10 percent, 55 patients are effective to 27.5 percent, 5 patients are ineffective to 2.5 percent, and the total effective rate is 97.5 percent.
Typical cases
Mr. Liu, 55 years old, married, enterprise workers, ill for 7 years, according to the self-statement that cerebral infarction diseases occur once in No. 1 month and No. 7 night sleep in 2010, families find in time that the first hospital in Yulin city is sent for rescue, according to the medical record display, 220/130mmHg of blood pressure, the patient shows symptoms such as facial distortion, odontoseisis, hemiplegia, running water and the like clinically, the illness state is stabilized in time in the case of rescue due to the well-being, after 1 course of treatment of the medicine, the clinical symptoms of the patient are improved, the measured blood pressure is 140/100mmHg, after 3 courses of treatment, the patient is refreshed in spirit and healthy, and has no relapse.
In conclusion, the medicine for treating hypertension and cerebral infarction has special effect on treating hypertension and cerebral infarction diseases, blood pressure of a patient can be quickly restored to be normal after treatment, and especially, the patient with the cerebral infarction diseases does not have antecedent symptoms such as facial distortion, numbness of limbs, unclear mouth and teeth, hemiplegia, watery mouth, dizziness and the like, so that the physical condition is restored to be normal.
The invention takes notes that: is suitable for patients with obesity due to qi deficiency and blood stasis, and is administered in dosage considering weight factor, and is forbidden for patients with cerebral hemorrhage and hemorrhage in certain part of body, and women stop taking during menstrual period.
Claims (4)
1. The medicine for treating hypertension and cerebral infarction is characterized by comprising the following raw materials in parts by weight:
15-50 parts of astragalus membranaceus, 10-40 parts of salvia miltiorrhiza, 10-30 parts of hawthorn, 8-32 parts of gynostemma pentaphylla, 2-30 parts of medicinal cyathula root, 2-30 parts of caulis spatholobi, 2-20 parts of notopterygium root, 1-15 parts of frankincense, 1-15 parts of myrrh, 2-25 parts of peach kernel, 2-25 parts of safflower, 2-25 parts of cassia twig, 2-25 parts of ramulus mori, 2-25 parts of red paeony root, 2-18 parts of ligusticum wallichii, 2-18 parts of angelica sinensis, 2-20 parts of earthworm, 2-30 parts of gastrodia elata, 5-35 parts of uncaria, 4-30 parts of selfheal, 2-18 parts of leech, 2-30 parts of herba siegesbeckiae, 2-30 parts of eucommia ulmoides and 2-25.
2. The medicine for treating hypertension and cerebral infarction as claimed in claim 1, wherein the weight ratio of each raw material is:
25-40 parts of astragalus membranaceus, 15-35 parts of salvia miltiorrhiza, 12-25 parts of hawthorn, 16-22 parts of gynostemma pentaphylla, 8-22 parts of medicinal cyathula root, 8-22 parts of caulis spatholobi, 8-15 parts of notopterygium root, 4-11 parts of frankincense, 4-11 parts of myrrh, 6-18 parts of peach kernel, 6-18 parts of safflower, 6-18 parts of cassia twig, 6-18 parts of ramulus mori, 6-18 parts of red peony root, 5-12 parts of ligusticum wallichii, 5-12 parts of angelica sinensis, 8-15 parts of earthworm, 8-22 parts of gastrodia elata, 10-25 parts of uncaria, 10-22 parts of selfheal, 5-12 parts of leech, 8-22 parts of herba siegesbeckiae, 8-22 parts of eucommia ulmoides and 6-18 parts.
3. The medicine for treating hypertension and cerebral infarction as claimed in claim 1, wherein the weight ratio of each raw material is:
35 parts of astragalus membranaceus, 25 parts of salvia miltiorrhiza, 20 parts of hawthorn, 18 parts of gynostemma pentaphylla, 10 parts of medicinal cyathula root, 10 parts of caulis spatholobi, 9 parts of notopterygium root, 5 parts of frankincense, 5 parts of myrrh, 8 parts of peach kernel, 8 parts of safflower, 8 parts of cassia twig, 8 parts of ramulus mori, 8 parts of red paeony root, 6 parts of ligusticum wallichii, 6 parts of angelica sinensis, 9 parts of earthworm, 10 parts of rhizoma gastrodiae, 15 parts of uncaria, 12 parts of selfheal, 6 parts of leech, 10 parts of herba siegesbeckiae, 10 parts of eucommia ulmoides and.
4. A preparation method of a medicine for treating hypertension and cerebral infarction is characterized by comprising the following steps: the seven doses of the raw materials are taken according to the weight portion proportion of claim 3, the raw materials are filled into a medicine bag and sealed, 5000-6000 ml of water is added for soaking for 1 hour, then the soaked water and the medicine bag are filled into an automatic medicine decocting machine, decoction is carried out for forty-five minutes by slow and strong fire, dregs are removed after decoction liquid is taken out, the medicine liquid is bagged by a machine, each bag is 200ml, and the medicine liquid is placed in a refrigerator for cold storage for standby.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611258660.5A CN106474356A (en) | 2016-12-30 | 2016-12-30 | A kind of medicine of logical stalkization bolt and preparation method thereof |
| CN2016112586605 | 2016-12-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108261505A CN108261505A (en) | 2018-07-10 |
| CN108261505B true CN108261505B (en) | 2020-09-25 |
Family
ID=58285265
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611258660.5A Withdrawn CN106474356A (en) | 2016-12-30 | 2016-12-30 | A kind of medicine of logical stalkization bolt and preparation method thereof |
| CN201711056389.1A Active CN108261505B (en) | 2016-12-30 | 2017-10-27 | Medicine for treating hypertension and cerebral infarction and preparation method thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611258660.5A Withdrawn CN106474356A (en) | 2016-12-30 | 2016-12-30 | A kind of medicine of logical stalkization bolt and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN106474356A (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7158831B2 (en) * | 2017-06-30 | 2022-10-24 | 小林製薬株式会社 | Tablet containing goshitsu processed material |
| CN111759958B (en) * | 2020-07-15 | 2021-08-20 | 黑龙江中医药大学 | Medicine device is spouted in thrombus clearance |
| CN112891432A (en) * | 2021-04-09 | 2021-06-04 | 湖南三真康复医院股份有限公司 | A Chinese medicinal granule for treating apoplexy and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1520862A (en) * | 2003-01-29 | 2004-08-18 | 赵步长 | Prepared traditional Chinese medicine for apoplexy and obstruction of qi in the chest |
-
2016
- 2016-12-30 CN CN201611258660.5A patent/CN106474356A/en not_active Withdrawn
-
2017
- 2017-10-27 CN CN201711056389.1A patent/CN108261505B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1520862A (en) * | 2003-01-29 | 2004-08-18 | 赵步长 | Prepared traditional Chinese medicine for apoplexy and obstruction of qi in the chest |
Non-Patent Citations (1)
| Title |
|---|
| 中西医结合治疗老年缺血性中风——附对脑血流影响的观察;潘金友等;《辽宁中医杂志》;20000131;第27卷(第01期);第29页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108261505A (en) | 2018-07-10 |
| CN106474356A (en) | 2017-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108261505B (en) | Medicine for treating hypertension and cerebral infarction and preparation method thereof | |
| CN105288230A (en) | Traditional Chinese medicine composition for treating paralysis | |
| CN105250813A (en) | Chinese herb composition for treating jaundice | |
| CN104491733A (en) | Application of traditional Chinese medicine preparation in preparation of medicines for treating anemia, deficiency of vital energy and debilitation | |
| CN103550688B (en) | A kind of Chinese medicine composition for the treatment of cardiopalmus | |
| CN105311492A (en) | Medicine for treating coronary atherosclerotic heart disease | |
| US20030143289A1 (en) | Herbal composition PHY828 and its use | |
| CN101628074A (en) | Medical composition | |
| CN108186749A (en) | Treat Chinese medicine composition of cervical spondylosis and preparation method thereof | |
| CN100515462C (en) | Chinese medicine for treating cardiovascular and cerebrovascular trrombus and preparing method | |
| CN1977839A (en) | Medicinal composition for treating cerebrovascular disease and its preparing method | |
| CN103142897B (en) | Medicine used after esophageal achalasia operation | |
| CN105311210A (en) | Pharmaceutical composition for treating rheumatoid bone diseases | |
| CN104984268A (en) | Traditional Chinese medicine composition treating cerebral thrombosis and preparing method of traditional Chinese medicine composition | |
| CN104721631A (en) | Traditional Chinese medicine composition for promoting wound healing and preparation method of traditional Chinese medicine composition | |
| CN104758652A (en) | Traditional Chinese medicine composition for treating dizziness | |
| CN104547489A (en) | Use of traditional Chinese medicine composition in preparation of medicine for treating comminuted fracture | |
| CN1613471A (en) | Preparation of compound pseudo-ginseng drop pellets for treating traumatologic disease | |
| CN103285108B (en) | Chinese medicinal composition treating lumbago | |
| CN106729327A (en) | It is a kind of to treat qi-blood deficiency and renal deficiency type irregular menstruation Chinese medicine composition | |
| CN102114211A (en) | Chinese herbal medicine for treating hepatopathy | |
| CN105816819A (en) | Method for preparing traditional Chinese medicine composition for treating cerebral thrombosis | |
| CN101745084A (en) | The Chinese medicine preparation that is used for the central nervous system injury rehabilitation | |
| CN105381175A (en) | Application of traditional Chinese medicine composition in preparation of drugs for treating coronary artery diseases | |
| CN105362610A (en) | Traditional Chinese medicine composition for treating coronary artery diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |